Alzamend Neuro is trading at $1.59 (-6.47%) after its September 10, 2026 Form 10-Q disclosed a $3.027 million net loss and no product revenue.
- The filing raised substantial doubt about the company’s ability to continue as a going concern, likely pressuring shares.
- Broader markets were positive on September 11, 2026, so the decline appears company-specific.
- Earlier clinical-development updates and funding news were overshadowed; trading activity is live, but reliable volume data was unavailable.